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line was designated as the index date. Patients’ pharmacy claims
were followed for one year after their index dates. Adherence
with RAS therapy was measured by medication possession ratio
(MPR). Prescription copay was measured by a ﬂat dollar amount
paid for RAS therapy, normalized at days of supply level. Regres-
sion analyses were adopted to analyze the effects of copay on
adherence with RAS therapy. Other control variables included
age, gender, comorbidities, concomitant medications (b-blockers,
statins, calcium channel blockers), and the step-therapy care
program. RESULTS: The results show that of the 799 heart
failure patients, 457 (57%) received RAS therapy. 48% of the
457 patients were adherent (MPR  0.8), 22% were partially
adherent (0.5 MPR < 0.8) and 30% were non-adherent
(MPR < 0.5). Prescription copay had a signiﬁcant negative effect
on adherence, which meant higher copayment led to lower adher-
ence rates such that for every $1 increase in prescription copay,
adherence decreased by 9%. Of the controlling variables, only
age had a positive impact on adherence where older individuals
were more compliant with RAS therapy than younger people.
CONCLUSION: Approximately 4 out of 10 patients did not
receive recommended pharmacotherapy with RAS agents after a
heart failure event. Furthermore, only half of those patients who
received RAS therapy were considered adherent. Higher prescrip-
tion copay was associated with lower adherence to RAS therapy.
WITHDRAWN PCV62
PCV63
BARRIERS AND MOTIVATORS ASSOCIATEDWITH
ADHERENCETO ANTIHYPERTENSIVE MEDICATIONS AND
BLOOD PRESSURE CONTROL AMONG AFRICAN AMERICANS
FROM ALABAMA
Salas M
University of Alabama at Birmingham, Birmingham, AL, USA
OBJECTIVE: African Americans (AAs) have higher prevalence
of hypertension and worse cardiovascular and renal outcomes
than Caucasians. Previous studies have shown that adherence to
antihypertensive medications is lower in African Americans
than Caucasians. Limited information is available on behavioral
factors associated with medication adherence in African
Americans. Therefore, our objective was to determine the bar-
riers and motivators associated with adherence to antihyperten-
sive medications and blood pressure control among African
Americans living in Alabama. METHODS: A cross-sectional
study sampled adult AAs outpatients with a diagnosis of hyper-
tension that were receiving at least one antihypertensive medi-
cation, were residents of Jefferson County and had signed the
informed consent. A face to face interview was conducted by
three previously trained and certiﬁed interviewers that adminis-
tered a computer-assisted structured questionnaire to collect
survey data on demographics, medical history and behavioral
measures (medication adherence, self-efﬁcacy, and barriers and
motivators). RESULTS: Seven hundred and forty eight AAs par-
ticipated: 71% women, 85% older than 45 years of age, 59%
ﬁnished high school, and 87% had annual family income
<$5000. Forty percent of participants adhered to antihyperten-
sive medications. There were statistically signiﬁcant differences
in diastolic blood pressure between adherent (80  14) and
non-adherent patients (83  15, p = 0.03). Compared to non-
adherent patients, more adherent patients took their medica-
tions as directed because they felt they were doing something to
reduce their blood pressure (p = 0.030), felt their disease was
under control (p = 0.001) and felt more responsible (p = 0.033).
A higher proportion of adherent patients overcome barriers
such as taking medications when they were busy at home
(p = 0.0001), when they were working (p = 0.001), or when
they were in public places (p = 0.001). CONCLUSION: Adher-
ent patients were able to overcome barriers for medication
adherence. Interventions focused on motivators have the
potential for improving blood pressure control in high-risk
populations.
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OBJECTIVE: The main purpose of this study was to evaluate the
impact of Statin Step Care (SC) Program on patient compliance.
METHODS: Using a pre-post self case-control approach, pre-
scription records were obtained from de-identiﬁed pharmacy
claims database maintained by a large pharmacy beneﬁt manager
(PBM). To be included in the analysis, SC program enrollees were
deﬁned as having at least one generic statin prescription on or
after May 1, 2007 (index date) and any brand name statin
prescription history before the index date. The case group was
comprised of statin prescription records of enrollees four months
before and after the index date. All eligible patients were also
checked for their continuous enrollment during the study period.
Statin prescription records of the same enrollees group in a
similar timeframes of 2006 were obtained as a control group.
Compliance was assessed in terms of medication possession ratio
(MPR), deﬁned as sum of days that patient possessed any statin
medication divided by the total number of days in the follow-up
period. MPR was calculated for the pre and post periods and
compared using paired t-test. RESULTS: A total of 4122 claims
and 451 eligible enrollees were included in the analysis. For the
study group, mean MPR increased from 0.8347 to 0.8571
(p-value = 0.0304) from the pre-period to the post-period.
However, in the control group, the mean MPR increased slightly
from 0.8540 to 0.8554 (p-value = 0.8709), and the difference
was not found to be statistically signiﬁcant. CONCLUSION: A
signiﬁcant increase in the MPR was observed in the study group
patients after the statin step care program implementation. The
study suggests that the statin SC program could have improved
the patient compliance. However, further prospective studies are
needed to establish the cause-effect relationship between SC
program and patient compliance.
PCV65
CHANGE IN HEALTH-RELATED QUALITY OF LIFE
FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN
POST-MYOCARDIAL INFARCTION PATIENTS
Lewis EF1, Li Y2, Pfeffer MA1, Solomon SD1,Weinfurt KP2,
Velázquez EJ3, Califf R3,White HD4, Rouleau JL5, Schulman KA2,
Reed SD2
1Brigham and Women’s Hospital, Boston, MA, USA, 2Duke Clinical
Research Institute, Durham, NC, USA, 3Duke University Medical
Center, Durham, NC, USA, 4Auckland City Hospital, Auckland, New
Zealand, 5Montreal Heart Institute, Montreal, Quebec, Canada
OBJECTIVE: To determine the impact of subsequent cardiovas-
cular (CV) events on change in preference-based measures of
HRQL in patients who previously experienced an acute myocar-
dial infarction using data from the VAlsartan IN Acute Myocar-
dial iNfarcTion (VALIANT) trial. METHODS: Patients in the
VALIANT HRQL sub-study completed the EQ-5D, including the
visual analogue scale (VAS) rescaled to 0–1, at baseline, and 6,
12, 20, and 24 months. All EQ-5D assessments from baseline
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through the ﬁrst assessment following a CV event were retained.
Patients who experienced multiple events or died prior to the
next EQ-5D assessment were excluded from the main analysis.
Random-effects regression models, speciﬁed with random inter-
cepts and slopes, were used to model linear trajectories of utility
weights and VAS scores across time. To evaluate the impact of a
CV event (hospitalization for heart failure, recurrent acute myo-
cardial infarction, stroke, and resuscitated sudden death/cardiac
arrest), the mean trajectory change between the observed HRQL
scores following the CV event and the expected HRQL scores
based on the patients’ pre-event trajectories were estimated.
RESULTS: Among 14,703 adult patients enrolled in VALIANT,
2,556 patients were eligible for HRQL sub-study and completed
baseline EQ5D. Among the 504 patients who experienced a
nonfatal CV event, the trajectory-adjusted mean change follow-
ing the event was -0.07 (95%CI: -0.1 to -0.03; P = 0.0007)
based on UK utility weights, -0.05 (95%CI: -0.08 to -0.01;
P = 0.0082) based on US utility weights, and -0.06 (95%CI:
-0.08 to -0.03; P < 0.0001) based on VAS scores. Differences
between results using utility weights and VAS scores were most
notable for patients suffering a non-fatal stroke with trajectory
adjusted mean change scores of -0.26 with UK utility weights,
-0.22 with US utility weights, and -0.06 with VAS. CONCLU-
SION: Post-MI patients who suffered a subsequent cardiovascu-
lar event experienced a signiﬁcant decrease in HRQL.
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OBJECTIVE: Our aims were: 1) to determine whether proxy
responses to generic health related quality of life (HRQL) mea-
sures are responsive to meaningful patient improvement in the
six months following ischemic stroke; 2) to compare the respon-
siveness of generic measures by proxy assessment; and 3) to
compare proxy to patient responsiveness. METHODS: This sec-
ondary analysis of a longitudinal cohort study of ischemic stroke
patients and caregivers (n = 124 at baseline; n = 98 at 6 months)
included the following HRQL measures: EQ-5D Index, EQ-5D
VAS, HUI2, HUI3, and SF-6D. Patients were categorized as
improved from baseline to 6 months based on improvement in
Barthel Index (BI) categories (mild: 85; moderate: 60 to <85;
severe: <60). Responsiveness was compared on the basis of effect
size (ES) statistics for the baseline to 6 month interval. RESULTS:
Stroke patients were primarily male (52%), average 67 (SD 15)
years, and had primarily severe stroke (59% categorized as
severe by BI). Proxies tended to be female (67%) and either a
spouse (48%) or child (32%) of the stroke patient. Among
patients who improved according to the BI, all proxy-assessed
measures demonstrated large magnitudes of change (ES > 0.80).
The SF-6D was the most responsive measure (ES = 1.36; boot-
strapped 95% CI: 0.95–1.89), while the HUI3 was least respon-
sive (ES = 0.99, bootstrapped 95% CI: 0.69–1.40), although
bootstrapped 95% CIs overlapped for all measures. ES estimates
were not signiﬁcantly different for proxy raters compared to
patient self-report (all bootstrapped CIs overlapped). However,
the ES for proxy-rated VAS scores was 50% greater than patient
report while indirect utility measures tended to produce compa-
rable levels of responsiveness or were larger according to patient
self-report. CONCLUSION: Proxy assessments of stroke
patients were responsive to meaningful change using the VAS,
EQ-5D, SF-6D, HUI2, and HUI3 during the initial post-stroke
recovery process, capturing large magnitudes of changes similar
to patient assessments.
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OBJECTIVE: To study clinical determinants of satisfaction and
health-related quality of life (HRQoL) in patients with cardiac
disease and dyslipidemia. METHODS: A prospective, cross sec-
tional study was conducted using a questionnaire. The ques-
tionnaire containing SF-12v1 general health survey (range
0–100), the MacNew Heart disease health-related quality of life
instrument (range 1–7), and questions regarding satisfaction
with care (range 1–7) and demographics were administered to
randomly selected patients seeking care in a secondary preven-
tion lipid clinic. A unique de-identiﬁed patient code was
matched with medical charts to obtain clinical information.
Descriptive analyses and stepwise regression analyses were con-
ducted to assess study objectives. RESULTS: A total of 124
participants (65.7% male) completed the survey; response rate
was 72.9%. Physical (PCS) and mental (MCS) component
summary scores of the SF-12v1 scale were 37.3 (  9.2) and
49.1 (  9.7), respectively. The scores of the MacNew scale
domains were physical (5.2  1.3), emotional (5.2  0.9),
social (5.5  1.3), and global (5.2  1.0), respectively. In
general, the participants in the study were satisﬁed with the
care provided (4.28  0.62). Multivariate analysis indicated
that LDL levels (b = -0.37) and triglycerides levels (b = -0.26)
signiﬁcantly (p < 0.05) predicted the MCS scores, while drug
type (b = -0.51) and gender (b = -0.32) signiﬁcantly (p < 0.05)
predicted PCS scores. With respect to the MacNew scale, LDL
levels (b = -0.29), triglycerides (b = -0.22), and diastolic blood
pressure (b = 0.28) signiﬁcantly (p < 0.05) predicted emotional
scores, while drug type (b = -0.26) signiﬁcantly (p < 0.05) pre-
dicted physical scores. Further, LDL goals achieved (b = 0.22)
and BMI (b = -0.27) signiﬁcantly (p < 0.05) predicted satisfac-
tion with care. CONCLUSION: Results suggest that LDL
levels, triglycerides levels, and drug type used signiﬁcantly
affected HRQoL as measured by both scales and LDL goals
achieved BMI signiﬁcantly affected satisfaction with care. This
information is valuable for future interventional studies aiming
to improve HRQoL and satisfaction with care provided after
cardiac disease and may aid physicians’ decisions while provid-
ing care.
PCV69
CONVENIENCE OFTHE NEW LONG-ACTING
ANTICOAGULANT IDRAPARINUXVERSUSVITAMIN K
ANTAGONIST IN PATIENTSWITH ATRIAL FIBRILLATION
Prins MH1, Leguet P2, Gilet H3, Roborel de Climens A3,Arnould B3
1Maastricht University, Academic Hospital Maastricht, Maastricht,
Netherlands, 2Sanoﬁ-Aventis, Paris Cedex 13, France, 3Mapi Values
France, Lyon, France
OBJECTIVE: A major goal of a new anticoagulant therapy is to
alleviate the burden associated with treatment by Vitamin K
Antagonist (VKA). However, advantages such as simpliﬁed
administration and monitoring or reduced lifestyle constraints
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